Home - Clear Your View

YOU’RE IN THE DRIVER’S SEAT

when making treatment decisions for your advanced NSCLC patients

Test for ALL 10 NCCN Guideline Biomarkers

The Clear Facts

Just 18% of advanced NSCLC patients get complete testing before first-line treatment. Only testing for all 10 biomarkers delivers complete answers.

% OF PATIENTS TESTED

*at the time of the study 2016-2018 excludes PD-L1, KRAS, NTRK. | Diagram 1 Click here for complete references

Immunotherapy without complete testing is not effective for every NSCLC patient. Incomplete testing can mean sub-optimal patient outcomes.

PATIENTS w/ TARGETABLE ALTERATIONS

Diagram 2 Click here for complete references

A 3 year retrospective study showed the percent of patients not being tested for any biomarkers increased, and that the majority of community oncologists are still relying on single gene panels that miss NCCN guideline-recommend biomarkers.

Diagram 3 Click here for complete references

See The Data

YOUR ROADMAP FOR COMPLETE BIOMARKER TESTING

Only the right testing drives the right treatment decisions

STOP

Test every newly diagnosed NSCLC patient for all 10 NCCN guideline biomarkers. Every time.

NCCN Guidelines

Wait

Wait for complete results to determine the most effective therapy.

PATIENT BROCHURE

Treat

Confidently choose the best possible first-line treatment - targeted therapy or immunotherapy +/- chemotherapy.

Comprehensive reference card

Patients are demanding:

"What is stopping you from testing all of your lung cancer patients?"

Growing patient awareness

A thriving community of patient organizations advocate for complete testing before treatment.